Literature DB >> 26207203

Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014.

Eugene J Wyatt1, H Lee Sweeney2, Elizabeth M McNally3.   

Abstract

The New Directions in the Biology and Disease of Skeletal Muscle is a scientific meeting, held every other year, with the stated purpose of bringing together scientists, clinicians, industry representatives and patient advocacy groups to disseminate new discovery useful for treatment inherited forms of neuromuscular disease, primarily the muscular dystrophies. This meeting originated as a response the Muscular Dystrophy Care Act in order to provide a venue for the free exchange of information, with the emphasis on unpublished or newly published data. Highlights of this years' meeting included results from early phase clinical trials for Duchenne Muscular Dystrophy, progress in understanding the epigenetic defects in Fascioscapulohumeral Muscular Dystrophy and new mechanisms of muscle membrane repair. The following is a brief report of the highlights from the conference.

Entities:  

Year:  2014        PMID: 26207203      PMCID: PMC4508866          DOI: 10.3233/JND-149003

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  89 in total

Review 1.  An innate sense of danger.

Authors:  Polly Matzinger
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

2.  Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice.

Authors:  C Florian Bentzinger; Patrizia Barzaghi; Shuo Lin; Markus A Ruegg
Journal:  FASEB J       Date:  2005-06       Impact factor: 5.191

3.  Rapid actin-cytoskeleton-dependent recruitment of plasma membrane-derived dysferlin at wounds is critical for muscle membrane repair.

Authors:  Joel R McDade; Ashley Archambeau; Daniel E Michele
Journal:  FASEB J       Date:  2014-05-01       Impact factor: 5.191

4.  Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice.

Authors:  Renzhi Han; Ellie M Frett; Jennifer R Levy; Erik P Rader; John D Lueck; Dimple Bansal; Steven A Moore; Rainer Ng; Daniel Beltrán-Valero de Bernabé; John A Faulkner; Kevin P Campbell
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

5.  Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD).

Authors:  Weihua Zeng; Jessica C de Greef; Yen-Yun Chen; Richard Chien; Xiangduo Kong; Heather C Gregson; Sara T Winokur; April Pyle; Keith D Robertson; John A Schmiesing; Virginia E Kimonis; Judit Balog; Rune R Frants; Alexander R Ball; Leslie F Lock; Peter J Donovan; Silvère M van der Maarel; Kyoko Yokomori
Journal:  PLoS Genet       Date:  2009-07-10       Impact factor: 5.917

6.  Cellular microenvironments reveal defective mechanosensing responses and elevated YAP signaling in LMNA-mutated muscle precursors.

Authors:  Anne T Bertrand; Simindokht Ziaei; Camille Ehret; Hélène Duchemin; Kamel Mamchaoui; Anne Bigot; Michèle Mayer; Susana Quijano-Roy; Isabelle Desguerre; Jeanne Lainé; Rabah Ben Yaou; Gisèle Bonne; Catherine Coirault
Journal:  J Cell Sci       Date:  2014-05-07       Impact factor: 5.285

7.  Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system.

Authors:  Xiaoju Wang; Huadong Fan; Zheng Ying; Bin Li; Hongfeng Wang; Guanghui Wang
Journal:  Neurosci Lett       Date:  2009-11-26       Impact factor: 3.046

8.  RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.

Authors:  Krzysztof Sobczak; Thurman M Wheeler; Wenli Wang; Charles A Thornton
Journal:  Mol Ther       Date:  2012-11-27       Impact factor: 11.454

9.  Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages.

Authors:  Sarina Meinen; Patrizia Barzaghi; Shuo Lin; Hanns Lochmüller; Markus A Ruegg
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

10.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Authors:  Burcu Ayoglu; Amina Chaouch; Hanns Lochmüller; Luisa Politano; Enrico Bertini; Pietro Spitali; Monika Hiller; Eric H Niks; Francesca Gualandi; Fredrik Pontén; Kate Bushby; Annemieke Aartsma-Rus; Elena Schwartz; Yannick Le Priol; Volker Straub; Mathias Uhlén; Sebahattin Cirak; Peter A C 't Hoen; Francesco Muntoni; Alessandra Ferlini; Jochen M Schwenk; Peter Nilsson; Cristina Al-Khalili Szigyarto
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

View more
  1 in total

Review 1.  Current and emerging treatment strategies for Duchenne muscular dystrophy.

Authors:  Jean K Mah
Journal:  Neuropsychiatr Dis Treat       Date:  2016-07-22       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.